Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06833996 · ClinicalTrials.gov registry record · NA
The Efficacy of Bakuchiol in Treating PIH
A NA study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT06833996 is a NA study that has completed, run by Henry Ford Health System. The registered enrollment target is 22 participants.
The verdict
NCT06833996, a NA study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
Post-inflammatory hyperpigmentation (PIH) is an acquired hyper melanosis that occurs after cutaneous inflammation or injury frequently affecting darker skinned individuals. Bakuchiol is derived from plants and has inhibitory effects on melanin synthesis, which makes it a promising therapeutic intervention in the management of PIH. This study aims to evaluate the efficacy of bakuchiol in treating post inflammatory hyperpigmentation using the investigators previously validated model in comparison to acne induced PIH.
Interventions
- DRUG Vehicle
- DRUG Bakuchiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-02-22 |
| Est. Completion | 2019-05-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06833996
The ClinicalTrials.gov registry entry for NCT06833996 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT06833996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06833996 about?
NCT06833996 is a clinical study titled "The Efficacy of Bakuchiol in Treating PIH". Post-inflammatory hyperpigmentation (PIH) is an acquired hyper melanosis that occurs after cutaneous inflammation or injury frequently affecting darker skinned individuals. Bakuchiol is derived from plants and has inhibitory effects on melanin synthesis, which makes it a promising therapeutic interv...
What is the current status of trial NCT06833996?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2016-02-22. Estimated completion is 2019-05-05.
What interventions are being tested in trial NCT06833996?
The interventions under investigation include: Vehicle (DRUG), Bakuchiol (DRUG).
Who is sponsoring clinical trial NCT06833996?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.